Scope Fluidics S.A.

Warsaw Stock Exchange SCP.WA

Scope Fluidics S.A. Price to Sales Ratio (P/S) on January 14, 2025: 835.38

Scope Fluidics S.A. Price to Sales Ratio (P/S) is 835.38 on January 14, 2025, a -27.62% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Scope Fluidics S.A. 52-week high Price to Sales Ratio (P/S) is 1,185.69 on January 24, 2024, which is 41.93% above the current Price to Sales Ratio (P/S).
Scope Fluidics S.A. 52-week low Price to Sales Ratio (P/S) is 708.80 on December 19, 2024, which is -15.15% below the current Price to Sales Ratio (P/S).
Scope Fluidics S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 921.99.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Warsaw Stock Exchange: SCP.WA

Scope Fluidics S.A.

CEO	Mr. Piotr Garstecki
IPO Date	Aug. 1, 2017
Location	Poland
Headquarters	9th floor
Employees	40
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Scope Fluidics S.A., a biotechnology company, engages in the designing and developing projects based on microfluidic technologies in medical diagnostics and healthcare. It offers BacterOMIC, an antibiotic susceptibility testing. The company was founded in 2010 and is based in Warsaw, Poland.

Key trends

Past 5 years